Advanced

MicroRNAs in the failing heart - Novel therapeutic targets?

Gidlöf, Olof LU and Erlinge, David LU (2014) In Scandinavian Cardiovascular Journal 48(6). p.328-334
Abstract
Abstract Heart failure is a common and disabling disease with high mortality that carries substantial societal costs. Current therapeutic strategies are aimed at relieving symptoms, avoiding hospitalization, and prolonging life, but disease progression is ultimately inevitable. MicroRNAs (miRNAs) are short, non-coding RNA molecules with pervasive roles in eukaryotic biology, annealing to complimentary sites on target mRNAs, and repressing gene expression. The fact that miRNAs are dysregulated in many human disorders, including cardiovascular disease, and the relative ease with which endogenous miRNA expression can be altered using synthetic antisense oligos has stirred enthusiasm for these molecules as potential drug targets. The aim of... (More)
Abstract Heart failure is a common and disabling disease with high mortality that carries substantial societal costs. Current therapeutic strategies are aimed at relieving symptoms, avoiding hospitalization, and prolonging life, but disease progression is ultimately inevitable. MicroRNAs (miRNAs) are short, non-coding RNA molecules with pervasive roles in eukaryotic biology, annealing to complimentary sites on target mRNAs, and repressing gene expression. The fact that miRNAs are dysregulated in many human disorders, including cardiovascular disease, and the relative ease with which endogenous miRNA expression can be altered using synthetic antisense oligos has stirred enthusiasm for these molecules as potential drug targets. The aim of this review article was to summarize the current knowledge on the roles of miRNA in the pathophysiology of heart failure as well as the use of miRNAs as therapeutic targets and diagnostic tools for the disease. (Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
Scandinavian Cardiovascular Journal
volume
48
issue
6
pages
328 - 334
publisher
Taylor & Francis
external identifiers
  • pmid:25375881
  • wos:000345601200002
  • scopus:84913621141
ISSN
1651-2006
DOI
10.3109/14017431.2014.983965
language
English
LU publication?
yes
id
c9b264ae-5d1d-49ae-9211-c720c7839cfe (old id 4820168)
alternative location
http://www.ncbi.nlm.nih.gov/pubmed/25375881?dopt=Abstract
date added to LUP
2014-12-01 19:28:08
date last changed
2017-09-10 03:08:18
@article{c9b264ae-5d1d-49ae-9211-c720c7839cfe,
  abstract     = {Abstract Heart failure is a common and disabling disease with high mortality that carries substantial societal costs. Current therapeutic strategies are aimed at relieving symptoms, avoiding hospitalization, and prolonging life, but disease progression is ultimately inevitable. MicroRNAs (miRNAs) are short, non-coding RNA molecules with pervasive roles in eukaryotic biology, annealing to complimentary sites on target mRNAs, and repressing gene expression. The fact that miRNAs are dysregulated in many human disorders, including cardiovascular disease, and the relative ease with which endogenous miRNA expression can be altered using synthetic antisense oligos has stirred enthusiasm for these molecules as potential drug targets. The aim of this review article was to summarize the current knowledge on the roles of miRNA in the pathophysiology of heart failure as well as the use of miRNAs as therapeutic targets and diagnostic tools for the disease.},
  author       = {Gidlöf, Olof and Erlinge, David},
  issn         = {1651-2006},
  language     = {eng},
  number       = {6},
  pages        = {328--334},
  publisher    = {Taylor & Francis},
  series       = {Scandinavian Cardiovascular Journal},
  title        = {MicroRNAs in the failing heart - Novel therapeutic targets?},
  url          = {http://dx.doi.org/10.3109/14017431.2014.983965},
  volume       = {48},
  year         = {2014},
}